torcetrapib

(redirected from CETP inhibitor)

torcetrapib

A cholesterol ester transfer protein (CETP) inhibitor drug that has been shown capable of substantially increasing levels of high density lipoprotein (HDL) cholesterol. A major trial of this drug in conjunction with atorvastatin was stopped by Pfizer at the end of 2006.
References in periodicals archive ?
Dr Louise Bowman, the other co-principal investigator of REVEAL, explained: The REVEAL trial recruited around twice as many participants as any other trial of a CETP inhibitor, collected information on double the number of cardiovascular events, and gave CETP treatment for twice as long.
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Frishman, "Evacetrapib: another CETP inhibitor for dyslipidemia with no clinical benefit," Cardiology in Review, vol.
And Amgen announced in September that it would pay at least $300 million to buy Dezima Pharma, a privately held Dutch company that has a CETP inhibitor ready to enter the final stage of clinical testing.
Amgen gains itsTA-8995 oral, once-daily CETP inhibitor in development for use in patients with mild dyslipidemia.
The team at Forbion recognized early on the potential of TA-8995, an oral, once-daily CETP inhibitor and helped to found, fund and staff the company, including in-licensing this lead asset from Mitsubishi Tanabe Pharma Corp.
The potential future therapeutic options for targeted Lp(a) control include cholesterol-ester transfer protein inhibitors (CETPI), anti-sense oligonucleopeptides (ASO) and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK-9I) and L-carnitine.22,23 The CETP inhibitor Anacetrapib has been shown to reduce Lp(a) plasma levels by up to 50%.24 The ASO Mipomersen lowers Lp(a) by up to 50% in phase 2 trials with single injections given fortnightly.25 Maximum reductions occur after 3-6 months of continuous therapy, and slowly return to baseline after cessation of therapy.25 The PCSK-9I, AMG-145, has similar effects on Lp(a) levels with once monthly injections.26 Carnitine supplementation therapy in doses of up to 1gm daily leads to 10-15% reduction (Table-2).23,24
Results of another study of a CETP inhibitor, dalcetrapib, were presented at the American Heart Association annual meeting in November 2012 and published simultaneously in the New England Journal of Medicine.
18 November 2010 - US pharmaceutical company Merck and Co Inc (NYSE: MRK) said yesterday that its investigational CETP inhibitor anacetrapib has met safety and efficacy endpoints in patients with coronary heart disease (CHD) in a Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study.
Indeed, the drug company Pfizer, based in New York, is currently testing a CETP inhibitor as a promoter of heart health.
The first CETP inhibitor, torcetrapib, proved unsuccessful because it increased levels of aldosterone, a hormone that increases blood pressure.
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.